Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Rahmawati, Risya Amelia
- In Silico Study and In Vitro test of Extract Kaempferia pandurata Roxb. as Anti ER (+) Breast Cancer Cell Line MCF-7
Abstract Views :280 |
PDF Views:0
Authors
Fadilah
1,
Lowilius Wiyono
2,
Brenda Cristie Edina
2,
Risya Amelia Rahmawati
2,
Linda Erlina
1,
Aryo Tedjo
1,
Rafika Indah Paramita
3
Affiliations
1 Departement of Medical Chemistry, University of Indonesia, ID
2 University of Indonesia, ID
3 Indonesian Medical Education and Research Institute, University of Indonesia, ID
1 Departement of Medical Chemistry, University of Indonesia, ID
2 University of Indonesia, ID
3 Indonesian Medical Education and Research Institute, University of Indonesia, ID
Source
Research Journal of Pharmacy and Technology, Vol 12, No 5 (2019), Pagination: 2391-2395Abstract
Breast cancer most commonly occurs in women worldwide, in 2012 there were 1.670.000 cases with the second most prevalence in the world (25% of the total incidence of cancer). Drugs used so far have not been effective and many resistance occurs, it is necessary to a discovery of herbs that contain polyphenols as anticancer. Kaempferia pandurata Roxb plant has been identified to contain various essential oils and several flavonoid compounds that have demonstrated many biological activities. This research was done by simulation study with molecular docking approach which then extraction, the result of the extract was tested in vitro activity against Breast Cancer Cell Line MCF-7. The docking results show that the flavonoid compound against the target ERbreast cancer has an enthalpy energy ΔG -11.75 kcal/mol, the phytochemical results support that the flavonoids compound dominates the composition of the Kaempferia pandurata Roxb. The Result of in vivo test with MTT method IC50 value of standard cisplatin, hexane extract was 8.42; 26.70 μg/ml respectively to MCF-7 cell line showed that Kaempferia pandurata Roxb extract very potential as an antibreast cancer.Keywords
Molecular Docking, Phytochemical Test, Antibreast Cancer, Kaempferia pandurata Roxb., MCF-7 Cell Line.
References
- National Cancer Institute. Hormone Therapy for Breast Cancer. 2012. Available from: URL: http://www.cancer.gov/cancertopics/ types/breast/breast-hormone-therapy-fact-sheet
- Lim, E.; Metzger-Filho, O.; Winer, E.P. The natural history of hormone receptor-positive breast cancer. Oncology, 2012, 26, 688694.
- Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005; 65: 11071-11082
- Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18: 1-32 [PMID: 14687595]
- Kao Y-C, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 1998; 106:85–92.
- Elfahmi, Woerdenbag, HJ, Kayser, O. Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use. Journal of Herbal Medicine 2014; 4:51-73.
- Rukayadi, Y, Lee, K, Han, S, Yong, D, Hwang, JK. In vitro activities of panduratin A against clinical Staphylococcus strains. Antimicrobial agents and chemotherapy 2009; 53:4529-32.
- Tewtrakul, S, Subhadhirasakul, S, Karalai, C, Ponglimanont, C, Cheenpracha, S. Anti-inflammatory effects of compounds from Kaempferia parviflora and Boesenbergia pandurata. Food Chemistry 2009; 115:534-8.
- Kirana, C, Jones, GP, Record, IR, McIntosh, GH. Anticancer properties of panduratin A isolated from Boesenbergia pandurata (Zingiberaceae). Journal of Natural Medicines 2007; 61:131-7.
- Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011; 7:146–57.
- Yuriev E, Agostino M, Ramsland PA. Challenges and advances in computational docking: 2009 in review. J Mol Recognit. 2011; 24:149–64.
- Jamil K, Mustafa SM. (2012). Thioredoxin System: A model for determining novel lead molecules for breast cancer chemotherapy. AJMB 4: 3.
- Covell DG, Huang R, Wallqvist A. Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Mol Cancer Ther 2007; 6: 2261–2270.
- Takimoto CH. Anticancer drug development at the US National Cancer Institute. Cancer Chemother Pharmacol 2003; 52 Suppl 1: S29–S33.
- Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero D, Monks A, Boyd MR. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus aprotein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82:1113-1118.
- S. Madhuri and Govind Pandey, Some anticancer medicinal plants of foreign Origin, current science 2009; 96(6-25):145-148.
- https://www.ncbi.nlm.nih.gov/protein/602617469 18. Pouget C, Lauthier F, Simon A, Fagnere C, Basly J-P, Delage C, et al. Flavonoids: structural requirements for antiproliferative activity on breast cancer cells. Bioorg Med Chem Lett 2001; 11:3095–7.